CUE
Cue Biopharma Inc

1,387
Mkt Cap
$37.58M
Volume
337,852.00
52W High
$1.75
52W Low
$0.4747
PE Ratio
-1.05
CUE Fundamentals
Price
$0.4966
Prev Close
$0.4773
Open
$0.498
50D MA
$0.6876
Beta
1.35
Avg. Volume
388,195.32
EPS (Annual)
-$0.7221
P/B
2.80
Rev/Employee
$226,512.20
Loading...
Loading...
News
all
press releases
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates
Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.00% and -14.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·29d ago
News Placeholder
More News
News Placeholder
CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates
CERVOMED INC (CRVO) delivered earnings and revenue surprises of -23.53% and -69.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates
Puma Biotech (PBYI) delivered earnings and revenue surprises of +133.33% and +12.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +6.25% and +38.15%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of -32.58% and +24.16%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.77% and +47.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of +74.07% and +5.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -13.33% and -2.19%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates
Zacks·7mo ago

Latest CUE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.